Real-world clinical utility (effectiveness) of omalizumab as add-on therapy in patient with difficult-to-treat severe allergic asthma

Background: Severe allergic asthma (SAA) requires high-dose inhaled corticosteroids and additional medications. It poses a substantial health and financial burden. Omalizumab, an antibody that targets IgE, has improved symptoms and quality of life in severe allergic asthma (SAA) patients. Its impact...

Cijeli opis

Bibliografski detalji

Glavni autori:	Rowshne Jahan, Ziaul Huq
Format:	Artigo
Jezik:	Inglês
Izdano:	Elsevier 2025-01-01
Serija:	Current Research in Pharmacology and Drug Discovery
Teme:	Asthma Severe allergic asthma Humanized monoclonal antibody Omalizumab Immunoglobulin E Pulmonary function test
Online pristup:	http://www.sciencedirect.com/science/article/pii/S2590257125000069
Oznake:	Dodaj oznaku Bez oznaka, Budi prvi tko označuje ovaj zapis!